Search clinical trials for: Interferon beta-1a-matching placebo

Total 2745 results

Bayer

Completed

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b (ADHERENCE)

Multiple Sclerosis
Bayer

Completed

Betaferon® Regulatory Post-Marketing Surveillance

Multiple Sclerosis | Clinically Isolated System

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

REbif FLEXible Dosing in Early Multiple Sclerosis (MS) (REFLEX)

Multiple Sclerosis

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Turkey, Estonia, Germany, Latvia, Poland, Romania, Argentina, Israel, Portugal, Greece, Czech Republic, Slovakia, Serbia, Austria, Finland, Saudi Arabia, Belgium, Canada, Lebanon and more
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Bayer

Terminated

Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting

France
Bayer

Completed

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron (START)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)

Multiple Sclerosis

France
Bayer

Completed

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Bayer

Completed

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (BetaSleep)

Multiple Sclerosis

Germany
Bayer

Completed

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (POR-BetaPlus)

Secondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)

Portugal
Bayer

Completed

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
University of Chicago

Unknown

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Immune System Diseases | Multiple Sclerosis

United States
Claudio Gobbi
Ospedale Civico, Lugano

Completed

Natalizumab De-escalation With Interferon Beta-1b

Relapsing-remitting Multiple Sclerosis

Switzerland
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Bayer

Completed

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Recruiting

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)

Multiple Sclerosis

Germany, Spain, Italy, France, United Kingdom
Shahid Beheshti University of Medical Sciences

Unknown

Interferon Beta 1a in Hospitalized COVID-19 Patients (IB1aIC)

COVID-19

Iran, Islamic Republic of
University of Pennsylvania
National Cancer Institute (NCI); Biogen

Completed

Gene Therapy for Pleural Malignancies

Pleural Mesothelioma | Metastatic Pleural Effusions

United States
Bayer

Completed

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Multiple Sclerosis, Relapsing-Remitting

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); EMD Serono

Terminated

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Stage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus Infection

United States
Institut National de la Santé Et de la Recherche...

Completed

Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)

Corona Virus Infection

Norway, Austria, France, Greece, Portugal, Belgium, Luxembourg
Bayer

Completed

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Multiple Sclerosis, Relapsing Remitting

Belgium, Bosnia and Herzegovina, Italy, Austria, Croatia, Czechia, France, Greece, Hungary, Spain, Switzerland
Bayer

Withdrawn

QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Multiple Sclerosis, Relapsing-Remitting

Korea, Republic of
Biogen

Completed

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

Healthy Volunteers

United States
German University in Cairo

Recruiting

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Multiple Sclerosis

Egypt
Biogen

Completed

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (Avonex China)

Multiple Sclerosis

China
Pfizer

Completed

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Dermatomyositis

United States, Spain, Hungary, Poland
Bayer

Completed

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study (PROmyBETAapp)

Multiple Sclerosis

Germany
Biogen
Elan Pharmaceuticals

Completed

Treatment Interruption of Natalizumab (RESTORE)

Relapsing Remitting Multiple Sclerosis

United States, Germany, Spain
Claudio Gobbi
Bayer

Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (RELIEF)

Multiple Sclerosis, Relapsing-Remitting

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

Ulcerative Colitis

United States
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
MidAmerica Neuroscience Research Foundation at...
Consultants in Neurology

Withdrawn

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Multiple Sclerosis | Optic Neuritis | Neuritis | Myelitis | Demyelinating Disorders

United States
Biogen

Completed

Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (PERSIST)

Multiple Sclerosis

Sweden, France, United Kingdom, Germany, Denmark, Netherlands, Slovakia, Switzerland, Norway, Portugal
Shahid Beheshti University of Medical Sciences

Unknown

Umifenovir in Hospitalized COVID-19 Patients (UAIIC)

COVID-19

Iran, Islamic Republic of
M.D. Anderson Cancer Center

Completed

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

Ovarian Cancer

United States
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
University Hospital Inselspital, Berne
PharmaPart; Viollier AG, Basel, Switzerland

Completed

Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b

Relapsing-remitting Multiple Sclerosis

Switzerland
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
Novartis Pharmaceuticals

Completed

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (Cognition)

Multiple Sclerosis

Italy, Germany
Clinique de sclérose en plaques et neuromusculaire...

Unknown

Combination Therapy of Betaseron-Prograf in Multiple Sclerosis

Multiple Sclerosis

Canada
University of North Carolina

Completed

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

Multiple Sclerosis

United States
The University of Hong Kong

Completed

Double Therapy With IFN-beta 1b and Hydroxychloroquine

COVID

Hong Kong
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Evobrutinib in Participants With RMS

Relapsing-remitting Multiple Sclerosis

United States, Germany
The University of Hong Kong

Unknown

IFN-beta 1b and Remdesivir for COVID19

Covid19

Hong Kong
EMD Serono
Merck Serono International SA

Completed

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Relapsing-remitting Multiple Sclerosis

United States, Germany

Search clinical trials for: Interferon beta-1a-matching placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations